Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Postherpetic Neuralgia in Herpes Zoster

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients of 50 years of age and older.~* Patients with a clinical diagnosis of uncomplicated herpes zoster presenting within the first 72 hours of vesicles.~* Patients who are willing and able to comply with the requirements of the study.~* Patients who are willing and able to give written informed consent.~* Average pain score pre-therapy greater or equal than 4 on 10-point Likert scale.~Exclusion Criteria:~* Sexually-active women of childbearing potential, including postmenopausal women less than 1 year since last menses, not employing adequate contraception (approved oral contraceptive, intrauterine device, barrier methods or total abstinence).~* Pregnant females and nursing mothers.~* Patients with immune dysfunction including congenital immune deficiency, active malignancy of any type, collagen vascular diseases, organ or bone marrow transplantations, known infection with HIV or severe atopic dermatitis.~* Patients who have received cytotoxic drugs or immunosuppressive therapy (e.g., chronic systemic corticosteroids) within the previous 3 months.~* Patients with evidence of cutaneous or visceral dissemination of herpes zoster infection (cutaneous dissemination is defined as \> 20 discrete lesions outside adjacent dermatomes).~* Patients who have received systemic anti-VZV medications or immunomodulatory medications (including interferon) within the previous 4 weeks.~* Patients currently receiving probenecid.~* Patients with impaired renal function: calculated creatinine clearance of \<30 mL/min using Cockcroft and Gault formula.~* Patients with abnormal liver function (alanine transaminase (ALT) or aspartate;transaminase (AST) levels greater than five times the upper limit of the normal range).~* Patients with a history of intolerance or hypersensitivity to acyclovir, penciclovir, valacyclovir, famciclovir or gabapentin.~* Patients currently receiving therapy with gabapentin or tricyclic antidepressants.~* Patients with clinical evidence of ocular involvement of herpes zoster. Patients with herpes zoster of the ophthalmic branch of the trigeminal nerve without evidence of ocular involvement will be included.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).